PRA Health Sciences Inc (PRAH) Analysts See $0.81 EPS

October 13, 2017 - By Marguerite Chambers

 PRA Health Sciences Inc (PRAH) Analysts See $0.81 EPS

Analysts await PRA Health Sciences Inc (NASDAQ:PRAH) to report earnings on November, 1. They expect $0.81 EPS, up 30.65 % or $0.19 from last year’s $0.62 per share. PRAH’s profit will be $50.71 million for 25.34 P/E if the $0.81 EPS becomes a reality. After $0.62 actual EPS reported by PRA Health Sciences Inc for the previous quarter, Wall Street now forecasts 30.65 % EPS growth. The stock increased 0.82% or $0.67 during the last trading session, reaching $82.11. About 338,886 shares traded. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 52.22% since October 13, 2016 and is uptrending. It has outperformed by 35.52% the S&P500.

PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage

Among 12 analysts covering PRA Health Sciences (NASDAQ:PRAH), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. PRA Health Sciences had 23 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Monday, February 6. The rating was upgraded by KeyBanc Capital Markets on Monday, June 13 to “Overweight”. Credit Suisse maintained PRA Health Sciences Inc (NASDAQ:PRAH) on Tuesday, August 8 with “Outperform” rating. Credit Suisse initiated the stock with “Neutral” rating in Tuesday, June 21 report. The rating was maintained by Robert W. Baird on Monday, October 9 with “Buy”. The rating was maintained by Jefferies on Thursday, June 1 with “Buy”. The company was reinitiated on Friday, August 14 by Credit Suisse. The stock has “Neutral” rating by SunTrust on Thursday, November 19. The stock has “Buy” rating by Citigroup on Thursday, September 22. On Monday, March 28 the stock rating was upgraded by SunTrust to “Buy”.

PRA Health Sciences, Inc. is a contract research organization. The company has market cap of $5.14 billion. The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It has a 53.38 P/E ratio. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

More notable recent PRA Health Sciences Inc (NASDAQ:PRAH) news were published by: Nasdaq.com which released: “Pra Health Sciences Inc (PRAH) President & CEO Colin Shannon Sold $29.9 …” on August 16, 2017, also Globenewswire.com with their article: “PRA Health Sciences to acquire Symphony Health Solutions, a leading provider …” published on August 07, 2017, Seekingalpha.com published: “PRA Health Sciences’ (PRAH) CEO Colin Shannon on Q1 2017 Results – Earnings …” on April 26, 2017. More interesting news about PRA Health Sciences Inc (NASDAQ:PRAH) were released by: Seekingalpha.com and their article: “PRA Health Sciences’ (PRAH) CEO Colin Shannon on Q2 2017 Results – Earnings …” published on August 12, 2017 as well as Prnewswire.com‘s news article titled: “Medical Research Stock Performance Review — OpGen, TearLab, TrovaGene, and …” with publication date: September 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.